AndrÃ©s F. Muro

List of Publications by Year
in descending order

84	3,804	147566	128067
papers	citations	31	60
		h-index	g-index

86	86	86	4808
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice. Frontiers in Genome Editing, 2022, 4, 785698.	2.7	8
2	Fludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice. Nature Biotechnology, 2022, 40, 1285-1294.	9.4	8
3	Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector. Molecular Therapy - Methods and Clinical Development, 2021, 20, 169-180.	1.8	12
4	Efficacy of AAV8-hUGT1A1Âwith Rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNs patients. Molecular Therapy - Methods and Clinical Development, 2021, 20, 287-297.	1.8	9
5	Low efficacy of recombinant SV40 in Ugt1a1-/- mice with severe inherited hyperbilirubinemia. PLoS ONE, 2021, 16, e0250605.	1.1	0
6	Beclinâ€1â€mediated activation of autophagy improves proximal and distal urea cycle disorders. EMBO Molecular Medicine, 2021, 13, e13158.	3.3	16
7	Long-Term Effects of Biliverdin Reductase a Deficiency in Ugt1â^'/â^' Mice: Impact on Redox Status and Metabolism. Antioxidants, 2021, 10, 2029.	2.2	3
8	Experimental models assessing bilirubin neurotoxicity. Pediatric Research, 2020, 87, 17-25.	1.1	14
9	A Quantitative InÂVitro Potency Assay for Adeno-Associated Virus Vectors Encoding for the UGT1A1 Transgene. Molecular Therapy - Methods and Clinical Development, 2020, 18, 250-258.	1.8	9
10	Human liver stem cells express UGT1A1 and improve phenotype of immunocompromised Crigler Najjar syndrome type I mice. Scientific Reports, 2020, 10, 887.	1.6	11
11	Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. Molecular Therapy - Methods and Clinical Development, 2019, 12, 157-174.	1.8	45
12	Gene Therapy in Pediatric Liver Disease. , 2019, , 799-829.		2
13	EDA fibronectinâ€“TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. Journal of Experimental Medicine, 2019, 216, 587-604.	4.2	36
14	Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases. JCI Insight, 2019, 4, .	2.3	28
15	Attenuation of neuro-inflammation improves survival and neurodegeneration in a mouse model of severe neonatal hyperbilirubinemia. Brain, Behavior, and Immunity, 2018, 70, 166-178.	2.0	39
16	Alternatively spliced fibronectin extra domain A is required for hemangiogenic recovery upon bone marrow chemotherapy. Haematologica, 2018, 103, e42-e45.	1.7	4
17	Bilirubin-Induced Oxidative Stress Leads to DNA Damage in the Cerebellum of Hyperbilirubinemic Neonatal Mice and Activates DNA Double-Strand Break Repair Pathways in Human Cells. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-11.	1.9	41
18	Advances in understanding disease mechanisms and potential treatments for Criglerâ€“Najjar syndrome. Expert Opinion on Orphan Drugs, 2018, 6, 425-439.	0.5	17

#	Article	IF	Citations
19	EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression. Blood, 2018, 132, 1781-1781.	0.6	3
20	Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Criglerâ€“Najjar Syndrome Type I. Gene Therapy, 2017, 24, 649-660.	2.3	27
21	Promoterless gene targeting without nucleases rescues lethality of a Criglerâ€Najjar syndrome mouse model. EMBO Molecular Medicine, 2017, 9, 1346-1355.	3.3	46
22	Inflammatory signature of cerebellar neurodegeneration during neonatal hyperbilirubinemia in Ugt1 -/- mouse model. Journal of Neuroinflammation, 2017, 14, 64.	3.1	34
23	Lack of Fibronectin Extra Domain A Alternative Splicing Exacerbates Endothelial Dysfunction in Diabetes. Scientific Reports, 2016, 6, 37965.	1.6	17
24	Modulation of bilirubin neurotoxicity by the Abcb1 transporter in theUgt1-/-lethal mouse model of neonatal hyperbilirubinemia. Human Molecular Genetics, 2016, 26, ddw375.	1.4	13
25	158. Cryptic ATG Removal from Synthetic Introns Increase the Therapeutic Efficacy of AAV Vector Mediated Gene Transfer. Molecular Therapy, 2016, 24, S62.	3.7	1
26	Absence of fibronectin-EDA contributes to sepsis outcomes in a murine model. Atherosclerosis, 2016, 252, e179.	0.4	1
27	A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16049.	1.8	50
28	Brief Report: Alternative Splicing of Extra Domain A (EIIIA) of Fibronectin Plays a Tissue-Specific Role in Hematopoietic Homeostasis. Stem Cells, 2016, 34, 2263-2268.	1.4	9
29	547. Untranslated Region Optimization Increases Transgene mRNA and Protein Levels, Resulting in Enhanced Therapeutic Efficacy of AAV Vector Gene Transfer In Vivo for Crigler-Najjar Syndrome. Molecular Therapy, 2015, 23, S219-S220.	3.7	0
30	688. AAV8-Mediated Liver Gene Targeting Without Nucleases Rescues Lethality in a Mouse Model of the Crigler-Najjar Syndrome. Molecular Therapy, 2015, 23, S274.	3.7	0
31	704. Long-Term Correction of Crigler-Najjar Syndrome and Scale-Up Production of an Optimized AAV8 Vector Expressing the UGT1A1 Transgene. Molecular Therapy, 2015, 23, S280-S281.	3.7	0
32	Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia. Scientific Reports, 2015, 5, 16203.	1.6	22
33	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. Thrombosis and Haemostasis, 2015, 114, 186-197.	1.8	21
34	Impairment of enzymatic antioxidant defenses is associated with bilirubin-induced neuronal cell death in the cerebellum of Ugt1 KO mice. Cell Death and Disease, 2015, 6, e1739-e1739.	2.7	33
35	TDP-43 regulatesÎ²-adducin(Add2) transcript stability. RNA Biology, 2014, 11, 1280-1290.	1.5	40
36	Age-dependent pattern of cerebellar susceptibility to bilirubin neurotoxicityin vivo. DMM Disease Models and Mechanisms, 2014, 7, 1057-68.	1.2	36

#	ARTICLE	IF	CITATIONS
37	Life-Long Correction of Hyperbilirubinemia with a Neonatal Liver-Specific AAV-Mediated Gene Transfer in a Lethal Mouse Model of Criglerâ€“Najjar Syndrome. Human Gene Therapy, 2014, 25, 844-855.	1.4	74
38	Generation of Ugt1-Deficient Murine Liver Cell Lines Using TALEN Technology. PLoS ONE, 2014, 9, e104816.	1.1	11
39	Extra domain-A fibronectin is necessary for the development of nasal remodeling in chronic allergen-induced rhinitis. Annals of Allergy, Asthma and Immunology, 2013, 110, 322-327.	0.5	5
40	EMILIN1/Î±9Î²1 Integrin Interaction Is Crucial in Lymphatic Valve Formation and Maintenance. Molecular and Cellular Biology, 2013, 33, 4381-4394.	1.1	62
41	Characterization of the Distal Polyadenylation Site of the ÃŸ-Adducin (Add2) Pre-mRNA. PLoS ONE, 2013, 8, e58879.	1.1	8
42	Long-distance regulation of Add2 pre-mRNA3â€²end processing. RNA Biology, 2013, 10, 516-527.	1.5	3
43	EDA-Containing Fibronectin Increases Proliferation of Embryonic Stem Cells. PLoS ONE, 2013, 8, e80681.	1.1	21
44	Rescue of bilirubinâ€induced neonatal lethality in a mouse model of Criglerâ€Najjar syndrome type I by AAV9â€mediated gene transfer. FASEB Journal, 2012, 26, 1052-1063.	0.2	71
45	Identification of 3â€² gene ends using transcriptional and genomic conservation across vertebrates. BMC Genomics, 2012, 13, 708.	1.2	5
46	Recipientâ€derived EDA fibronectin promotes cardiac allograft fibrosis. Journal of Pathology, 2012, 226, 609-618.	2.1	50
47	Stam2 expression pattern during embryo development. Gene Expression Patterns, 2012, 12, 68-76.	0.3	2
48	The extra domain AÂof fibronectin is essential for allergen-induced airway fibrosis and hyperresponsiveness in mice. Journal of Allergy and Clinical Immunology, 2011, 127, 439-446.e5.	1.5	27
49	Extra Domain A Fibronectin Promotes Fibrotic Remodeling In Chronic Cardiac Allograft Rejection. , 2011, , .		0
50	Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life, 2011, 63, 538-546.	1.5	141
51	Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway. Experimental Cell Research, 2010, 316, 2644-2653.	1.2	59
52	Î²â€adducin (Add2) KO mice show synaptic plasticity, motor coordination and behavioral deficits accompanied by changes in the expression and phosphorylation levels of the Î±â€and Î³â€adducin subunits. Genes, Brain and Behavior, 2010, 9, 84-96.	1.1	39
53	CPEB2, CPEB3 and CPEB4 are coordinately regulated by miRNAs recognizing conserved binding sites in paralog positions of their 3â€²-UTRs. Nucleic Acids Research, 2010, 38, 7698-7710.	6.5	25
54	EDAâ€containing cellular fibronectin induces fibroblast differentiation through binding to Î±₄Î²₇integrin receptor and MAPK/Erk 1/2â€dependent signaling. FASEB Journal, 2010, 24, 4503-4512.	0.2	130

#	Article	IF	Citations
55	Integrin-Î±9 Is Required for Fibronectin Matrix Assembly during Lymphatic Valve Morphogenesis. Developmental Cell, 2009, 17, 175-186.	3.1	290
56	New insights into form and function of fibronectin splice variants. Journal of Pathology, 2008, 216, 1-14.	2.1	288
57	Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis, 2008, 197, 534-540.	0.4	45
58	Prothrombotic Effects of Fibronectin Isoforms Containing the EDA Domain. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 296-301.	1.1	46
59	An Essential Role for Fibronectin Extra Type III Domain A in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 638-645.	2.5	257
60	A Major Fraction of Fibronectin Present in the Extracellular Matrix of Tissues Is Plasma-derived. Journal of Biological Chemistry, 2007, 282, 28057-28062.	1.6	104
61	Unexpected Rescue of Alpha-synuclein and Multimerin1 Deletion in C57BL/6JOlaHsd Mice by Beta-adducin Knockout. Transgenic Research, 2006, 15, 255-259.	1.3	8
62	Brain-specific promoter and polyadenylation sites of the Â-adducin pre-mRNA generate an unusually long 3'-UTR. Nucleic Acids Research, 2006, 34, 243-253.	6.5	201
63	A Polar Mechanism Coordinates Different Regions of Alternative Splicing within a Single Gene. Molecular Cell, 2005, 19, 393-404.	4.5	63
64	Impaired motor coordination in mice lacking the EDA exon of the fibronectin gene. Behavioural Brain Research, 2005, 161, 31-38.	1.2	21
65	RNA Folding Affects the Recruitment of SR Proteins by Mouse and Human Polypurinic Enhancer Elements in the Fibronectin EDA Exon. Molecular and Cellular Biology, 2004, 24, 1387-1400.	1.1	106
66	An Exonic Splicing Enhancer Offsets the Atypical GU-rich 3â€² Splice Site of Human Apolipoprotein A-II Exon 3. Journal of Biological Chemistry, 2004, 279, 39331-39339.	1.6	15
67	Alternative splicing of fibronectin: a mouse model demonstrates the identity of in vitro and in vivo systems and the processing autonomy of regulated exons in adult mice. Gene, 2004, 324, 55-63.	1.0	32
68	The erythrocyte skeletons of Î²-adducin deficient mice have altered levels of tropomyosin, tropomodulin and EcapZ. FEBS Letters, 2004, 576, 36-40.	1.3	17
69	Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. Journal of Cell Biology, 2003, 162, 149-160.	2.3	274
70	Hypertension-Linked Decrease in the Expression of Brain Î³-Adducin. Circulation Research, 2002, 91, 633-639.	2.0	22
71	Hypertension in Î²-Adducinâ€“Deficient Mice. Hypertension, 2000, 36, 449-453.	1.3	37
72	Structural and Functional Analysis of the cAMP Binding Domain from the Regulatory Subunit of Mucor rouxii Protein Kinase A. Archives of Biochemistry and Biophysics, 2000, 382, 173-181.	1.4	4

#	Article	IF	Citations
73	Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells. , 1999, 82, 748-753.		17
74	Coupling of Transcription with Alternative Splicing. Molecular Cell, 1999, 4, 251-258.	4.5	274
75	Regulation of the human apolipoprotein AIV gene expression in transgenic mice. FEBS Letters, 1999, 445, 45-52.	1.3	9
76	Regulation of Fibronectin EDA Exon Alternative Splicing: Possible Role of RNA Secondary Structure for Enhancer Display. Molecular and Cellular Biology, 1999, 19, 2657-2671.	1.1	123
77	Expression of RGD minus fibronectin that does not form extracellular matrix fibrils is sufficient to decrease tumor metastasis. , 1998, 78, 233-241.		16
78	Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exonic enhancer element and the 5â€² splicing site. FEBS Letters, 1998, 437, 137-141.	1.3	41
79	Characterisation and chromosomal localisation of the rat Î±- and Î²-adducin-encoding genes. Gene, 1995, 166, 307-311.	1.0	19
80	Genomic organisation and chromosomal localisation of the gene encoding human beta adducin. Gene, 1995, 167, 313-316.	1.0	19
81	Binding of nuclear factors to a satellite DNA of retroviral origin with marked differences in copy number among species of the rodentCtenomys. Nucleic Acids Research, 1994, 22, 656-661.	6.5	13
82	DNA sequencing by the chemical method: a 10 minute procedure for the G+A reaction. Trends in Genetics, 1993, 9, 337-338.	2.9	13
83	The CRE-binding factor ATF-2 facilitates the occupation of the CCAAT box in the fibronectin gene promoter. FEBS Letters, 1993, 327, 25-28.	1.3	24
84	Neurospora crassacDNA clones coding for a new member of therasprotein family. FEBS Letters, 1990, 273, 103-106.	1.3	17